Incytevs.Moderna
INCY vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Incyte and Moderna are similar in size by market cap; year to date, Moderna leads (+371.0% vs +29.6%).
Side by side
| INCY | MRNA | |
|---|---|---|
| Market cap | $24.4B | $25.2B |
| Price | $129.72 | $158.83 |
| Today | +1.4% | +14.4% |
| Return YTD | +29.6% | +371.0% |
| Return 1Y | +50.5% | +412.1% |
| P/E | 15.1 | — |
| P/S | 4.2 | 11.3 |
| P/B | 3.8 | 3.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →More INCY & MRNA comparisons
Other head-to-heads in the Biotech & innovation segment.
See where INCY and MRNA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →